High-Throughput Whole-Exome Sequencing and Large-Scale Computational Analysis to Identify the Genetic Biomarkers to Predict the Vedolizumab Response Status in Inflammatory Bowel Disease Patients from Saudi Arabia

High-Throughput Whole-Exome Sequencing and Large-Scale Computational Analysis to Identify the Genetic Biomarkers to Predict the Vedolizumab Response Status in Inflammatory Bowel Disease Patients from Saudi Arabia

<b>Background/Objectives</b>: Vedolizumab (VDZ) is the new monoclonal drug targeting α4β7 integrin for patients with moderate/severe IBD. Between 30 and 45% of patients fail to respond to VDZ after 14–16 weeks of treatment. The aim of the study was to explore the genetic profile of vedol...

Full description

Saved in:
Bibliographic Details
Main Authors: Hanin Aljohani, Doaa Anbarserry, Mahmoud Mosli, Amani Ujaimi, Duaa Bakhshwin, Ramu Elango, Sameer Alharthi
Format: Article
Language:English
Published: MDPI AG 2025-02-01
Series:Biomedicines
Subjects:
vedolizumab
genetic biomarkers
ulcerative colitis
Crohn’s disease
drug response
whole-exome sequencing
Online Access:https://www.mdpi.com/2227-9059/13/2/459
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/2227-9059/13/2/459

Similar Items